Was it worth introducing health economic evaluation of innovative drugs in the French regulatory setting? The case of new hepatitis C drugs
This paper constitutes the first attempt to draw lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.
Source: Value in Health - Category: International Medicine & Public Health Authors: Val érie Clément, Véronique Raimond Source Type: research
More News: France Health | Hepatitis | Hepatitis C | International Medicine & Public Health | Lessons | Men